Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Chronic Lymphocytic Leukemia: early-phase trial registry
7 of 20 indexed Refractory Chronic Lymphocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 7 currently recruiting · #848 of 28,707 conditions by registered trial count
Refractory Chronic Lymphocytic Leukemia: 20 US clinical trials tracked, 7 recruiting.
Refractory Chronic Lymphocytic Leukemia is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition refractory-chronic-lymphocytic-leukemia
OPEN 7 | RECR 35% | LATE 0 | EARLY 20 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Anatomic Stage IIIA Breast Cancer AJCC v8 (35% recruiting · 40 trials)
Refractory Chronic Lymphocytic Leukemia lists 7 open slots (35% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Chronic Lymphocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Chronic Lymphocytic Leukemia is recruiting below its size-band peers.
7 of 20 indexed trials (35%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Chronic Lymphocytic Leukemia research.
Fred Hutchinson Cancer Center accounts for 3 of 20 trials (15%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Chronic Lymphocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 24 among the 20 trials that report a genuine target (sentinel values excluded). 16 of those (80%) plan for fewer than 100 participants.
-
Refractory Chronic Lymphocytic Leukemia research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
NCT04169737
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
NCT06191887
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic
NCT04892277
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
NCT07166419
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
NCT07061951
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
NCT06839053
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
NCT04941716
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT02756897
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
NCT05828589
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia
Kerry Rogers
NCT02427451
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Jennifer R. Brown, MD, PhD
NCT04624633
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
NCT04007029
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
NCT03479268
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
NCT03961672
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02160015
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00105001
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT00303797
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Steven E. Coutre
NCT03045328
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
Mayo Clinic
NCT01269385
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Ohio State University Comprehensive Cancer Center
NCT01212380
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Chronic Lymphocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Chronic Lymphocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Chronic Lymphocytic Leukemia page
20 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Refractory Chronic Lymphocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Refractory Chronic Lymphocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Chronic Lymphocytic Leukemia condition card totals 20 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.